News
October 24, 2007 - Presented at the TCT 2007 meeting, a pooled analysis of safety data from Medtronic’s ENDEAVOR ...
October 24, 2007
News
October 25, 2007 - Study results presented at TCT 2007 demonstrated that the use of the isosmolar contrast medium ...
October 24, 2007News
October 25, 2007 - Abiomed Inc. announced for the first time, at TCT 2007, that the Impella 2.5 PROTECT I safety trial ...
October 24, 2007Sponsored Content
Feature | Information Technology
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
March 21, 2024News
October 25, 2007 — Two carotid stenting trials examining outcomes in real-world patients demonstrated for the first time results that are comparable to guidelines established by the American Heart Association (AHA) for patients treated with carotid artery surgery, the results of which were presented by William Gray, M.D., FACC, of Columbia University Medical Center in New York at TCT 2007.
October 24, 2007News
October 25, 2007 - Cordis Corp. announced at TCT 2007 the U.S. and European launch of Cordis’s next generation carotid stent system, the PRECISE PRO RX Nitinol Self-Expanding Stent, designed to treat clogged neck arteries and enable more efficient manipulation of the catheter and guidewire during stenting procedures and better crossability.
October 24, 2007News
October 25, 2007 - Global Therapeutics, a Cook Medical company, said at TCT 2007 it will begin a clinical trial using ...
October 24, 2007Sponsored Content
Feature | Cardiac Imaging
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
March 05, 2024News
October 24, 2007 – ev3 Inc. highlighted at TCT 2007 its merger with FoxHollow Technologies, Inc., which created an organization that possesses one of the largest U.S. distribution footprints in endovascular devices with combined technologies for the advancement of the treatment of peripheral and neurovascular disease.
October 23, 2007News
October 23, 2007 – After 12 months of the SPIRIT III trial, there were significantly fewer major adverse cardiac events (MACE) such as heart attacks, deaths from cardiac causes or repeat procedures (angioplasty or surgery) to clear the original vessel blockage after using a Xience V everolimus-eluting coronary stent than a Taxus paclitaxel-eluting stent, researchers reported at TCT 2007.
October 22, 2007News
October 23, 2007 - Toshiba America Medical Systems Inc. today announced that the first U.S. installation of the Infinix ...
October 22, 2007Sponsored Content
Blog
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
December 11, 2023News
October 23, 2007 - ENDEAVOR IV reached its primary endpoint of target vessel failure non-inferiority when compared to ...
October 22, 2007News
OCTOBER 23, 2007 – Abbott’s fully bioabsorbable drug eluting stent platform for the treatment of coronary artery disease ...
October 22, 2007News
October 23, 2007 - PLC Systems Inc. introduced at TCT 2007 the RenalGuard System, an investigational system and therapy ...
October 22, 2007Sponsored Content
Case Study | Hemodynamic Monitoring Systems
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
November 14, 2023News
October 23, 2007 - Hologic Inc.
October 22, 2007News
October 23, 2007 – Patients who received the CYPHER Sirolimus-eluting coronary stent had a lower risk of stent ...
October 22, 2007News
October 22, 2007 – A time-motion study conducted at Providence Heart Institute in Columbia, SC, spanning approximately ...
October 22, 2007© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now